Context Therapeutics® Announces Poster Presentation at the Upcoming 2022 ASCO Annual Meeting
May 05 2022 - 7:30AM
Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq:
CNTX), a women’s oncology company developing small molecule and
immunotherapy treatments for breast and gynecological
cancers, today announced that an abstract on the results of
the monotherapy portion of its ongoing Phase 2 trial of lead
candidate onapristone extended release (ONA-XR) in granulosa cell
tumors of the ovary was accepted for oral presentation at the 2022
American Society of Clinical Oncology (ASCO) Annual Meeting taking
place June 3-7, 2022, at the McCormick Place Convention Center in
Chicago, IL.
“We are thrilled that ASCO has recognized the potential of our
novel clinical program for ONA-XR, a potent, specific progesterone
receptor (PR) antagonist, in the treatment of granulosa cell tumors
(GCTs) of the ovary,” said Martin Lehr, CEO of Context
Therapeutics. “GCTs are a rare form of ovarian cancer that is
highly enriched for the target of ONA-XR. We look forward to
sharing the stage I monotherapy data at the conference and
continuing enrollment of the stage II portion evaluating the
combination of ONA-XR plus the antiestrogen anastrozole.”
Presentation details:
Title: Basket study of
oral progesterone antagonist onapristone extended release (ONA-XR)
in progesterone receptor positive (PR+) recurrent granulosa cell
(GCT), low-grade serous carcinoma ovarian (LGSOC), or endometrioid
endometrial cancer (EEC)Session
Type/Title: Poster Discussion Session, Gynecologic
CancerSession Date and
Time: Saturday, June 4, 2022; 1:15
PM - 4:15 PM CDTAbstract
Number: 5521Presenter: Rachel
Grisham, M.D., Memorial Sloan-Kettering Cancer Center
For more information, visit the ASCO Annual
Meeting website.
About Context
Therapeutics®Context Therapeutics Inc.
(Nasdaq: CNTX), is a women’s oncology company developing small
molecule and immunotherapy treatments to transform care for breast
and gynecological cancers. The Company’s robust clinical program
for lead candidate onapristone extended release (ONA-XR) comprises
three Phase 2 clinical trials and one Phase 1b/2 clinical trial in
hormone-driven breast, ovarian, and endometrial cancer. ONA-XR is a
novel, first-in-class small molecule under development as a potent
and specific antagonist of the progesterone receptor, a key
unchecked mechanism in hormone-driven women’s cancers. Context is
headquartered in Philadelphia, PA. For more information, visit
www.contexttherapeutics.com.
Forward-looking StatementsThis press release
contains “forward-looking statements” that involve substantial
risks and uncertainties for purposes of the safe harbor provided by
the Private Securities Litigation Reform Act of 1995. Any
statements, other than statements of historical fact, included in
this press release regarding strategy, future operations,
prospects, plans and objectives of management, including words such
as "may," "will," "expect," "anticipate," "plan," "intend," and
similar expressions (as well as other words or expressions
referencing future events, conditions or circumstances) are
forward-looking statements. These include, without limitation,
statements regarding (i) the results of our clinical trials, (ii)
the potential benefits of the product candidates, (iii) the
likelihood data will support future development, (iv) the ability
of the Company to participate in and present at conferences and
webinars, and (v) the likelihood of obtaining regulatory approval
of our product candidates. Forward-looking statements in this
release involve substantial risks and uncertainties that could
cause actual results to differ materially from those expressed or
implied by the forward-looking statements, and we, therefore cannot
assure you that our plans, intentions, expectations or strategies
will be attained or achieved. Other factors that may cause actual
results to differ from those expressed or implied in the
forward-looking statements in this press release are discussed in
our filings with the U.S. Securities and Exchange Commission,
including the section titled “Risk Factors” contained therein.
Except as otherwise required by law, we disclaim any intention or
obligation to update or revise any forward-looking statements,
which speak only as of the date they were made, whether as a result
of new information, future events or circumstances or
otherwise.
Media Contact:Gina Cestari6
Degrees917-797-7904gcestari@6degreespr.com
Investor Relations Contact:Laine YonkerEdison
Grouplyonker@edisongroup.com
Context Therapeutics (NASDAQ:CNTX)
Historical Stock Chart
From May 2024 to Jun 2024
Context Therapeutics (NASDAQ:CNTX)
Historical Stock Chart
From Jun 2023 to Jun 2024